Text version
Greetings! This is David Rosenberg from the Psychopharmacology Institute. In this CAP—Child and Adolescent Psychiatry—Smart Take, we will examine the impact of vortioxetine on the sleep architecture of adolescents diagnosed with major depressive disorder. This area of study is significant due to the ongoing challenges in antidepressant treatment and confirming their efficacy in adolescents suffering from major depressive disorder. Currently, only 2 FDA-approved antidepressants exist for treating major depressive disorder in this demographic: Fluoxetine and escitalopram.
Given the difficulty in identifying effective medication treatments for adolescent depression, an intriguing area of investigation involves objective signs, as opposed to a constellation of DSM criteria. Specifically, we are interested in sleep architecture and how it may bidirectionally relate to major depressive disorder. Sleep disturbance is a hallmark symptom of depression that requires adequate treatment; moreover, persistent sleep deprivation can exacerbate depression if left untreated and also adversely affect overall functioning.
The authors
Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
